Potency and mass of factor VIII in FVIII products

Haemophilia

Volumn 15, Issue 1, 2009, Pages 63-72

  Butenas, S ^a   Parhami seren, B ^a   Gissel, M T ^a   Gomperts, E D ^b   Fass, D N ^c   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Factor VIII activity; Factor VIII antigen; Factor VIII products; Intrinsic factor Xase; Thrombin generation; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; ASSAY; CONTROLLED STUDY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; WESTERN BLOTTING;

BLOTTING, WESTERN; CYSTEINE ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HUMANS; MALE; NEOPLASM PROTEINS; PARTIAL THROMBOPLASTIN TIME; PROTEOME; RECOMBINANT PROTEINS; REFERENCE STANDARDS;

EID: 63049114058     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01826.x     Document Type: Article

References (40)

1. Gitschier J, Kogan S, Diamond C, Levinson B. Genetic basis of hemophilia A. Thromb Haemost 1991; 66: 37-9.
2. Kekwick RA, Wolf P. A concentrate of human antihaemophilic factor -its use in six cases of haemophilia. Lancet 1957; i: 647.
3. Hoag MS, Johnson FF, Robinson JA, Aggeler PM. Treatment of hemophilia B with a new clotting-factor concentrate. N Engl J Med 1969; 28: 581-6.
4. Schulman S, Wiechel B. Hepatitis, epidemiology and liver function in hemophiliacs in Sweden. Acta Med Scand 1984; 215: 249-56.
5. Thompson AR. Factor IX concentrates for clinical use. Semin Thromb Hemost 1993; 19: 25-36.
6. Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001; 66: 229-40.
7. Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648-52.
8. Croissant MP, van de Pol H, Lee HH, Allain JP. Characterization of four monoclonal antibodies to factor VIII coagulant protein and their use in immunopurification of factor VIII. Thromb Haemost 1986; 56: 271-6.
9. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800-5.
10. Sandberg H, Almstedt A, Brandt J et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85: 93-100.
11. Gale AJ, Radtke K-P, Cunningham MA, Chamberlain D, Pellequer J-L, Griffin JH. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006; 4: 1315-22.
12. Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: Recovery, safety, efficacy, and inhibitor development. Semin Thromb Haemost 2002; 28: 273-6.
13. Suiter TM. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely? Semin Thromb Haemost 2002; 28: 278-83.
14. Miners AH. The economics of haemophilia treatments. In: Lee CH, Berntorp EE, Hoots KW, eds. Textbook of Hermophilia. Malden, MA: Blackwell Publishing, 2005: 351-8.
15. Barrowcliffe TW. Products used to treat hemophilia. In: Lee CH, Berntorp EE, Hoots KW, eds. Textbook of Hermophilia. Malden, MA: Blackwell Publishing, 2005: 242-8.
16. Kleinveld HA, Andersson NE, van Voorthuiozen H, den Hartog J, de Groot PG. Determination of coagulation factor VIII activity by a chromogenic substrate method on STA, an automated coagulation analyzer. Scand J Clin Invest 1999; 59: 335-41.
17. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 2 (Suppl. 4): 13-23.
18. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations. Semin Thromb Haemost 2002; 28: 247-55.
19. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Haemost 2002; 28: 257-64.
20. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity -assay discrepancies. Haemophilia 1998; 4: 641-5.
21. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
22. Butenas S, van't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272: 21527-33.
23. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-66.
24. van 't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 1997; 272: 4367-77.
25. Parhami-Seren B, Butenas S, Amblo J, Fass DN, Mann KG. Quantitation of FVIII antigen in human plasma. J Thromb Haemost 2005; 3 (Suppl. 1): P0650.
26. Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412.
27. Katzmann JA, Nesheim ME, Hibbard LS, Mann KG. Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci USA 1981; 78: 162-6.
28. Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-25.
29. Kumar H, Healey JF, Lollar P, Durrani MJ. Determination of free sulfhydryls in human factor VIII. J Thromb Haemost 2003; 1 (Suppl. 1): P1067.
30. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
31. Higgins DL, Mann KG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-8.
32. Precup JW, Kline BC, Fass DN. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage. Blood 1991; 77: 1929-36.
33. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268-78.
34. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
35. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
36. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-33.
37. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/ protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
38. Mathur A, Zhohg D, Sabharwal AK, Smith KJ, Bajaj SP. Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J Biol Chem 1997; 272: 23418-26.
39. Lollar P, Knutson GJ, Fass DN. Stabilization of thrombin-activated porcine factor VIII:C by factor IXa and phospholipid. Blood 1984; 63: 1303-8.
40. Lin Y, Yang X, Chevrier M-C et al. Relationships between factor VIII: Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.